Holen Sie sich die Stockscreener-App
5.67
1.25%
0.07
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Biotech Replimune Faces Derivative Suit Over Trial Claims - Law360
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. see short term momentum2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
US Bancorp DE Buys 3,921 Shares of Replimune Group, Inc. $REPL - Defense World
Using R and stats models for Replimune Group Inc. forecasting2025 Market Overview & Risk Managed Investment Entry Signals - Newser
What technical models suggest about Replimune Group Inc.’s comebackEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Is Replimune Group Inc. stock reversal real or fakePortfolio Profit Report & Verified Momentum Stock Alerts - Newser
Applying big data sentiment scoring on Replimune Group Inc.July 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Published on: 2025-08-19 23:50:57 - Newser
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma DrugHagens Berman - ACCESS Newswire
What moving averages say about Replimune Group Inc.Market Volume Report & Expert Curated Trade Setup Alerts - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - Newsfile
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
What earnings revisions data tells us about Replimune Group Inc.Weekly Profit Report & Community Trade Idea Sharing - Newser
How institutional ownership impacts Replimune Group Inc. stockQuarterly Growth Report & Weekly Top Performers Watchlists - Newser
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Replimune Group Inc.’s volatility index tracking explainedMarket Volume Report & High Win Rate Trade Tips - Newser
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact Levi & Korsinsky - MarketScreener
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before September 22, 2025 - ACCESS Newswire
Is Replimune Group Inc. a candidate for recovery playMarket Activity Summary & Expert Verified Stock Movement Alerts - Newser
How to interpret RSI for Replimune Group Inc. stockEarnings Miss & Breakout Confirmation Alerts - Newser
Replimune Group, Inc. Class Action: The Gross Law Firm - GlobeNewswire
Time to SueWallSt? Levi & Korsinsky Files Lawsuit Over Replimune Group, Inc. Stock Losses - Stockhouse
Class Action Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of September 22, 2025 Deadline - ACCESS Newswire
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL) - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
How to recover losses in Replimune Group Inc. stockPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
2025-08-17 | REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Is Replimune Group Inc. trending in predictive chart models2025 AllTime Highs & Verified Chart Pattern Trade Signals - Newser
REPL Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)Contact Kessler Topaz Meltzer & Check, LLP - FinancialContent
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmREPL - ACCESS Newswire
Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. (NASDAQ: REPL) - openPR.com
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. - MarketScreener
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. LawsuitREPL - PR Newswire
Replimune Group Stock Soars 17.76% Amid FDA Rejection Lawsuit - AInvest
Momentum divergence signals in Replimune Group Inc. chart2025 Biggest Moves & Safe Swing Trade Setups - Newser
Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
Replimune Group, Inc. shares rise 11.59% after-hours following securities class action lawsuits. - AInvest
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class - Bluefield Daily Telegraph
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):